DOCS Earnings

DOCS reported its FY2026Q3 earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 181.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.32 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DOCS's FY2026Q3 earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, DOCS's stock price tends to shift by an average of +2.87% in the 10 days leading up to earnings and +5.16% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate DOCS’s annual revenue to reach 182.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 1.63% and EPS estimates Revise Upward by 0.53% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DOCS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 1.63%, while EPS estimates moved Revise Upward by 0.53% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DOCS's stock price typically moves by +2.87% in the 10 days before its earnings and +5.16% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 0.00 and revenue of 182.00M.

The earnings call reveals strong financial performance with a 56% EBITDA margin and 15% revenue growth guidance. Product development is promising with AI investments and Pathway acquisition. Market strategy is robust, focusing on AI and health systems. Expenses are controlled with margins expected to remain stable. Shareholder return is not explicitly mentioned, but positive cash flow is anticipated. Q&A insights show optimism in AI and integrated programs, despite some uncertainties in policy impacts. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.